Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRS3 | P32247 | 12/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.34 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.34 |
| ▸ | GABBR2 | O75899 | 3/20 | 0.33 |
| ▸ | GABBR1 | Q9UBS5 | 3/20 | 0.33 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.33 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.33 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.33 |
| ▸ | CNR1 | P21554 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1605037 | 1.00 | BRS3 (0.35) | BRS3HPGDPDE3BPDE3AGABBR2 | |
| SCHEMBL1605035 | 1.00 | BRS3 (0.35) | BRS3HPGDPDE3BPDE3AGABBR2 | |
| SCHEMBL13998655 | 1.00 | BRS3 (0.35) | BRS3HPGDPDE3BPDE3AGABBR2 | |
| SCHEMBL13121912 | 1.00 | BRS3 (0.35) | BRS3HPGDPDE3BPDE3AGABBR2 | |
| SCHEMBL13998635 | 1.00 | BRS3 (0.35) | BRS3HPGDPDE3BPDE3AGABBR2 | |
| SCHEMBL1604934 | 1.00 | BRS3 (0.35) | BRS3HPGDPDE3BPDE3AGABBR2 | |
| SCHEMBL1606466 | 1.00 | BRS3 (0.35) | BRS3HPGDPDE3BPDE3AGABBR2 | |
| SCHEMBL1606464 | 1.00 | BRS3 (0.35) | BRS3HPGDPDE3BPDE3AGABBR2 | |
| SCHEMBL14429828 | 1.00 | BRS3 (0.35) | BRS3HPGDPDE3BPDE3AGABBR2 | |
| SCHEMBL1604938 | 1.00 | BRS3 (0.35) | BRS3HPGDPDE3BPDE3AGABBR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541592-B2 | Inhibitors of 11-beta-hydroxysteroid dehydrogenase type 1 | AMGEN INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20120010256-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | BIOVITRUM AB | 2012-01-12 | — | — | US | disclosed |
| US-20110082107-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC. | 2011-04-07 | — | — | US | disclosed |
| EP-1753736-B1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | AMGEN INC (US) | 2008-12-17 | — | — | EP | disclosed |
| US-20070281938-A1 | Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 | AMGEN INC. | 2007-12-06 | — | — | US | disclosed |
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | AMGEN INC. | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110082107-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD3B1, HSD17B1 | BRS3 2744/4885HPGD 84/4885PDE3B 766/4885 |
| US-20070197598-A1 | Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 | HSD11B1, HSD17B1, HSD11B2 | BRS3 3971/4885HPGD 43/4885PDE3B 1231/4885 |
| US-20120010256-A1 | INHIBITORS OF 11-BETA-HYDROXY STEROID DEHYDROGENASE TYPE 1 | HSD11B1, HSD3B1, HSD17B1 | BRS3 2744/4885HPGD 84/4885PDE3B 766/4885 |
| US-20070281938-A1 | Inhibitors of 11-Beta-Hydroxy Steroid Dehydrogenase Type 1 | HSD11B1, HSD3B1, HSD17B1 | BRS3 2763/4885HPGD 81/4885PDE3B 650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.